House dust mite allergy immunotherapy sublingual - HAL AllergyAlternative Names: SUBLIVAC FIX Mite
Latest Information Update: 07 Dec 2015
At a glance
- Originator HAL Allergy
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 14 Jan 2015 HAL Allergy initiates enrolment in a phase II trial for Allergic rhinitis and Rhinoconjunctivitis in Germany (EudraCT2014-002047-18)